SAKAR
OVERVALUEDSakar Healthcare Limited
Healthcare · NSE
↓ 426.5% vs fair value
52W Low
₹306
+147.7% from low
52W High
₹710
New 52W High 🚀
Valuation Gauge
Current Price
₹758
Fair Value
₹144
Fair Value Analysis
₹144
Based on free cash flow projections and balance sheet strength analysis and earnings growth potential for Healthcare sector companies | Growth capped at 9.9% (ROE 8.6%×1.15) — historical CAGR exceeds sustainable rate or COVID period unverifiable.
Cash Flow Analysis
40% weight
Balance Sheet Value
20% weight
Growth Valuation
40% weight
Price vs Market
Shareholding Pattern
Stock Health Score
Solid Fundamentals
Profitability
ROE of 10.0% is acceptable for Healthcare sector (benchmark: 15%)
Debt & Leverage
D/E ratio of 0.2x is well within the Healthcare sector norm of 0.8x — strong balance sheet
Valuation vs Peers
P/E of 51.0x trades at a 68% discount to Healthcare sector median (160x) — attractively valued
Cash Flow
FCF margin of 1.0% — very thin despite positive FCF (₹2 Cr)
Earnings Growth
5yr EPS CAGR of 4.7% is well below Healthcare sector average of 18.7%
Dividend
No dividend — typical for growth-stage companies
Company Health Timeline
10-year financial health at a glance
Sentiment Trend — Last 30 Days
Historical Returns
Key Financials
EPS (TTM)
₹13.7
P/E Ratio
51x
P/B Ratio
4.8x
ROE
10%
ROCE
8.4%
Debt / Equity
0.17x
Beta
—
Div Yield
—
FCF (Cr)
₹2 Cr
Revenue (Cr)
₹178 Cr
EPS Growth 5Y
4.7%
Mkt Cap (Cr)
₹1,529 Cr
52W High
₹709.7
52W Low
₹306
Book Value/Share
₹145.8
Financial History
| Period | Revenue | Op Profit | OPM% | PAT | EPS |
|---|---|---|---|---|---|
| 2026-03-31 | ₹252 Cr | ₹69 Cr | 27.0% | ₹30 Cr | ₹13.70 |
| 2025-03-31 | ₹178 Cr | ₹50 Cr | 28.0% | ₹18 Cr | ₹7.97 |
| 2024-03-31 | ₹153 Cr | ₹38 Cr | 25.0% | ₹12 Cr | ₹5.37 |
| 2023-03-31 | ₹133 Cr | ₹33 Cr | 25.0% | ₹13 Cr | ₹6.70 |
| 2022-03-31 | ₹128 Cr | ₹29 Cr | 23.0% | ₹15 Cr | ₹8.90 |
| 2021-03-31 | ₹95 Cr | ₹23 Cr | 24.0% | ₹11 Cr | ₹6.84 |
| 2020-03-31 | ₹83 Cr | ₹20 Cr | 24.0% | ₹10 Cr | ₹6.43 |
Compounded Growth Rates
Sales Growth
Profit Growth
EPS Growth
Peer Comparison
Healthcare| Stock | Price | Fair Value | MoS% | P/E | ROE | Signal |
|---|---|---|---|---|---|---|
Anlon Healthcare Limited | ₹13.9 | ₹50.7 | +72.6% | 20.5 | 7.3% | UNDERVALUED |
Alpa Laboratories Limited | ₹69.8 | ₹196.4 | +64.5% | 12.8 | 13.4% | FAIRLY_VALUED |
Aster DM Healthcare | ₹755.4 | ₹1,585.8 | +52.4% | 117.6 | 7.9% | UNDERVALUED |
Vimta Labs Limited | ₹453 | ₹722.6 | +37.3% | 26.2 | 18.6% | UNDERVALUED |
Unichem Laboratories Limited | ₹372.6 | ₹592.5 | +37.1% | 8.9 | 12.1% | FAIRLY_VALUED |
Dishman Carbogen Amcis Limited | ₹195.5 | ₹281.2 | +30.5% | 25.6 | 1.9% | FAIRLY_VALUED |
Indraprastha Medical Corporation Limited | ₹358.2 | ₹462.6 | +22.6% | 18.5 | 20.6% | UNDERVALUED |
Morepen Laboratories Limited | ₹43 | ₹52.8 | +18.5% | 23.3 | 10.8% | FAIRLY_VALUED |
Institutional Activity
Bulk deals, block deals, short selling & delivery volume — NSE data
Insider Trading
Community Pulse
Share this Stock
Download card · Share on WhatsApp
Share on WhatsApp, Twitter, or any group — each share brings new users to Veritas Quant